MaaT Pharma
Develops a series of microbiome-based drugs targeting mortality and comorbidities associated with blood cancer treatments.
Launch date
Employees
Market cap
€101m
Enterprise valuation
€90m (Public information from Sep 2024)
Share price
€7.14 MAAT.PA
Company register number 808370100
Lyon Auvergne-Rhône-Alpes (HQ)
Financials
Estimates*
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | <1m | 1.4m | 2.2m | 3.5m | 3.9m | 29.8m |
| % growth | - | - | 47 % | 56 % | 59 % | 11 % | 662 % |
| EBITDA | (5.1m) | (8.6m) | (13.1m) | (18.4m) | (30.2m) | (26.1m) | 3.5m |
| % EBITDA margin | - | (882 %) | (916 %) | (828 %) | (855 %) | (666 %) | 12 % |
| Profit | (5.3m) | (9.0m) | (13.7m) | (19.7m) | (31.2m) | (27.2m) | (26.2m) |
| % profit margin | - | (928 %) | (959 %) | (885 %) | (883 %) | (695 %) | (88 %) |
| EV / revenue | - | 97.2x | 38.6x | 25.4x | 29.2x | 30.5x | 61.6x |
| EV / EBITDA | - | -11.0x | -4.2x | -3.1x | -3.4x | -4.6x | 524.9x |
| R&D budget | 6.1m | 9.1m | 14.5m | 21.0m | - | - | - |
| R&D % of revenue | - | 941 % | 1012 % | 943 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
€1.0m | Early VC | ||
€1.0m | Seed | ||
€10.0m | Series A | ||
* | €18.0m | Series B | |
€7.4m Valuation: €90.0m -18.2x EV/LTM EBITDA | Series B | ||
$2.2m | Grant | ||
* | N/A | €31.0m | IPO |
* | €12.7m | Post IPO Equity | |
* | N/A | €18.2m | Post IPO Debt |
| Total Funding | €39.4m | ||
Related Content
Recent News about MaaT Pharma
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.